Table 1.

Study designs and outcomes of embolization procedures after PVE/HVE

Author	Year	Study design	Patients n	Type of tumor (only PVE/HVE)	HVE-technique	Embolized hepatic vein	Procedure-related complications n	Hospitals stay
Guiu et al. [15]	2016	Case series	PVE/HVE: 7	CRLM: 2 HCC:1 IHCC:3 PHCC:1	Transhepatic AVP + NBCA/lipiodol	RHV: 7	Pain: 5 Fever > 38°: 5	3 days (2–5)
Guiu et al. [25]	2017	Case series	PVE/HVE: 10	CRLM: 7 PHCC: 1 Other: 2	Transhepatic AVP + NBCA/lipiodol	RHV+MHV: 10	Asthenia Grade 2: 6 Grade 3: 2 Pain: 6 Fever > 38°: 3	3 days (2–5)
Le Roy et al. [26]	2017	Case series	PVE/HVE: 7	CRLM: 2 IHCC: 1 PHCC: 2 Other: 2	Transjugular AVP	RHV: 4 MHV: 2 RHV+MHV: 1	0	n.r.
Hocquelet et al. [27]	2018	Comparative study	PVE/HVE: 6 PVE: 6	PHCC: 6	Transjugular AVP	RHV: 6	0	24–48 h
Panaro et al. [28]	2019	Comparative study	PVE/HVE: 13 PVE: 16	CRLM: 10 HCC: 3	Transhepatic AVP + NBCA/lipiodol	RHV: 13	0	n.r.
Kobayashi et al. [29]	2020	Comparative study	PVE/HVE: 21* PVE: 39	CRLM: 10 HCC: 2 PHCC: 8	Transjugular AVP	RHV: 18 RHV+MHV: 2	Hemobilia: 1	n.r.
Le Roy et al. [30]	2020	Comparative study	PVE/HVE: 31 PVE: 41	CRLM: 18 HCC: 5 IHCC: 2 PHCC: 5 Other: 1	Transjugular AVP	RHV: 27 RHV+MHV: 3 MHV: 1	0	1 day
Laurent et al. [31]	2020	Comparative study	PVE/HVE: 37+ PVE:36	CRLM:23 IHCC: 7 HCC: 4 NET: 2	Transjugular AVP + NBCA/lipiodol	RHV: 29 RHV+MHV: 8	Dindo-Clavien: I: 34 II: 3	1.4 days (1–5)

n.r not reported, AVP Amplatzer Vascular Plug, CRLM colorectal liver metastasis, HCC hepatocellular carcinoma, IHCC intrahepatic cholangiocarcinoma, MHV middle hepatic vein, NBCA/lipiodol N-butyl-cyanoacrylate and iodized oil, NE: neuroendocrine tumor, PHCC perihilar cholangiocarcinoma, PVE portal vein embolization, PVE/HVE simultaneous portal and hepatic vein embolization, RHV right hepatic vein

^*Tumor type and information about the embolization were not given in one patient who failed to achieve liver resection

⁺Tumor type of one patient was not given